相关临床试验
668
63 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1819
进行中（未招募）
35
5.2%
已完成
313
46.9%
Enrolling By Invitation
4
0.6%
尚未招募
24
3.6%
招募中
111
16.6%
暂停
2
0.3%
终止
37
5.5%
Unknown
108
16.2%
撤回
34
5.1%
暂无批准数据
- Navion Neurosciences closed a $10.8 million first seed tranche led by the Angelini Lumira Biosciences Fund to advance precision sodium-channel therapeutics for genetic epilepsy and chronic neuropathic pain. - Proceeds will fund the company's preclinical lead programs and further development of its AI-enabled NaViGATion platform, which integrates AI chemistry, structural biology and ion-channel expertise. - The company aims to improve the therapeutic window of sodium-channel modulation, a limitation that has historically constrained broad-acting agents in epilepsy and pain. - Navion's leadership previously built Cavion, an ion-channel company acquired by Jazz Pharmaceuticals in 2019, and both lead programs remain preclinical.
- University of Virginia and Northwestern University researchers used targeted nanocarriers to identify Prox1 as a new genetic target within the eye's Schlemm's canal that can modify intraocular pressure. - The team created the first genetic mouse model with sustained elevated intraocular pressure, enabling better study of glaucoma and testing of potential cures. - Findings suggest a single-injection gene therapy could permanently lower intraocular pressure without daily eye drops or surgery, though human testing is at least five years away. - The work, published in JCI Insight, highlights how nanotechnology can serve both as a tool to understand disease and as a means for therapeutic intervention.
- Virginia Tech, UVA, VCU, and Old Dominion University launched the Biomedical Research Diamond to accelerate translation of discoveries into patient care. - The partnership combines expertise in basic science, engineering, clinical research, pharmaceutical development, and manufacturing that no single institution possesses. - Researchers presented advances spanning neuroscience, cancer, rare diseases, cardiovascular health, immunology, artificial intelligence, and drug discovery. - Leaders emphasized the initiative aims to retain scientific talent in Virginia while strengthening national security and economic competitiveness.
- The University of Virginia and its Manning Institute of Biotechnology have joined the SPARK GLOBAL initiative, a network of over 40 academic institutions worldwide dedicated to accelerating drug development. - SPARK GLOBAL provides researchers with funding access, mentorship, education, and specialized technical expertise to bridge the gap between academic discoveries and industry partners. - The original SPARK program at Stanford has achieved a 53% success rate, launching 63 startups, generating 30 licensing agreements, and advancing 25 projects into clinical trials since 2006. - UVA's participation aims to speed the development of treatments across cancer, infectious disease, autoimmune conditions, and other urgent healthcare challenges.
- University of Virginia researchers have created a new vaccine development platform that could produce vaccines for testing in just three weeks, significantly faster than the current 100-day pandemic response goal. - The innovative approach uses synthetic DNA and bacteria as vaccine factories, potentially costing less than $1 per dose while remaining stable at refrigerator temperatures without cold storage requirements. - Early testing demonstrates the platform can enhance vaccine immunogenicity by up to eight times compared to initial test vaccines, offering promise for rapid pandemic response. - The technology could enable vaccine manufacturing in existing facilities worldwide using abundant materials, making life-saving vaccines accessible even in remote and resource-limited areas.
- The Choroideremia Research Foundation acquired all assets related to Spark Therapeutics' SPK-7001 gene therapy program after the company discontinued development in 2025. - The acquired assets include intellectual property rights, biological materials, orphan drug designations, and Phase I/II clinical trial data from 15 participants. - CRF is analyzing five-year follow-up data with University of Virginia researchers to identify clinical endpoints that can establish vision stabilization following treatment. - The foundation aims to publish findings to inform regulatory action and approval for future research or clinical trials related to choroideremia treatments.
- University of Virginia researchers are initiating a clinical trial for a new COVID-19 treatment designed for non-hospitalized patients, working similarly to antiviral drugs for other infections. - The trial specifically targets vulnerable populations including adults aged 55 and older or those with weakened immune systems who have tested positive within five days. - Principal investigator Jeffrey Sturek emphasizes the continued importance of developing treatments for high-risk patients, noting COVID-19 remains a significant health threat requiring further therapeutic progress.
- Virginia lawmakers unanimously approved economic development packages worth over $10 million each for AstraZeneca's multibillion-dollar manufacturing plant in Albemarle County and Eli Lilly's facility in Goochland County. - The AstraZeneca project represents part of a $50 billion five-year investment plan and will be the company's largest global manufacturing investment, strategically located near the University of Virginia's Manning Institute of Biotechnology. - Both pharmaceutical giants are expanding domestic manufacturing capacity amid potential tariff threats, with Eli Lilly committing $50 billion over five years to double its U.S. manufacturing investments. - The Virginia facilities will strengthen a pharmaceutical manufacturing corridor extending from the Shenandoah Valley to Richmond, positioning the state as a major center for advanced pharmaceutical production.
- The University of Virginia has initiated a groundbreaking clinical trial testing a single 25-milligram dose of psilocybin to treat prolonged grief disorder, a clinically recognized condition affecting approximately 10% of mourning individuals. - The study, funded by an $895,866 grant from the Tiny Blue Dot Foundation, will enroll 20 participants and represents the first research of its kind at UVA. - Researchers hypothesize that psilocybin's ability to target serotonin receptors and induce heightened connectedness may help patients reframe their relationship with grief when traditional treatments like antidepressants and cognitive behavioral therapy prove insufficient.
- Skanska has secured an additional $66 million contract with the University of Virginia to construct the Paul and Diane Manning Institute of Biotechnology, bringing advanced translational research capabilities to the Commonwealth. - The 354,000-square-foot facility will feature modular laboratories, expanded research spaces, and dedicated areas for up to 150 researchers and biotechnology companies to collaborate on cutting-edge science. - Construction of this first-of-its-kind research program in Virginia began in December 2023 and is scheduled for completion in the fourth quarter of 2027.
